Companies › Intralytix
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Immunology, Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| EcoActive Bacteriophage preparation targeting adherent-invasive E. coli (AIEC) | – | Phase 1 | Crohn Disease | – |
| ShigActive Lytic bacteriophages targeting Shigella species | – | Phase 1 | Shigellosis; Endocarditis, Bacterial | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05182749 | ShigActive | Phase 1 | Shigellosis | Infectious disease | Dec 2024 |
| NCT03808103 | EcoActive | Phase 1 | Crohn Disease | Immunology | Jun 2026 |
| NCT06870409 | ShigActive | Phase 3 | Endocarditis, Bacterial | Infectious disease | Feb 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.